Fig. 5

CDC6 and EMT inversely correlate with GATA2 and senescence in enzalutamide-sensitive and -resistant prostate cancer samples in vitro and in vivo. A Publically available RNA-seq datasets of enzalutamide-sensitive (ENZA-S) and –resistant (ENZA-R) prostate cancer cell lines or mouse xenografts were retrieved and grouped to conduct pathway enrichment analyses. Pathways related to cell cycle transition, cell division and proliferation were predominant in ENZA-R samples versus pathways related to cell adhesion. See also Table S2. B mRNA CDC6 levels are significantly higher in ENZA-R than ENZA-S samples, and the opposite applies for GATA2. C ENZA-R samples display significantly higher expression of known EMT markers [49], including ZEB1 and SNAI1, compared to ENZA-S counterparts. In contrast, ENZA-R samples display significantly lower expression of senescence and SASP markers compared to ENZA-S samples. Senescence and SASP markers were retrieved from the Reactome online tool (https://www.reactome.org/content/detail/R-HSA-2559582). D Normalized RNA seq count-based heatmap from all datasets demonstrating that increased CDC6 in ENZA-R samples directly correlates with elevated EMT markers, however it is reciprocal to GATA2 levels and senescence markers. The exact opposite pattern is observed in ENZA-S samples